Consensus Aquestive Therapeutics, Inc.

Stocks

AQST

US03843E1047

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-09-09 EDT			5-day change	1st Jan Change
5.150 ^USD	-1.15%		-4.28%	-20.28%

08-12	Aquestive Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
08-11	Aquestive Therapeutics Q2 Loss Widens, Revenue Rises	MT

Evolution of the Average Target: Aquestive Therapeutics, Inc.

Evolution of the Target Price: Aquestive Therapeutics, Inc.

Changes in Analyst Recommendations: Aquestive Therapeutics, Inc.

7be36967e25da773.b2KiCBh2FmST3meFX5jLGxfpMJ9zr7TYY48BTGAd_zc.Vi6VO20pQy_4rhHHO_-nSVaHXeVFmOWiUvtTNjZNhnYsLupKYhF7MczuXw~83b87fbe39acc45b250128699acec3b8

Analysts' recommendations: Aquestive Therapeutics, Inc.

01-09	Top Midday Decliners	MT
11-04	Aquestive Therapeutics, Inc. Announces Executive Appointments	CI
25-09-08	Oppenheimer Adjusts Aquestive Therapeutics Price Target to $8 From $7, Maintains Outperform Rating	MT
24-12-17	Cantor Fitzgerald Initiates Aquestive Therapeutics at Overweight With $17 Price Target	MT
24-05-10	Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target	MT
24-04-11	Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target	MT
24-03-28	Raymond James Initiates Aquestive Therapeutics With Outperform Rating, $7 Price Target	MT
24-03-18	H.C. Wainwright Raises Price Target on Aquestive Therapeutics to $9 From $7, Maintains Buy Rating	MT
24-03-15	JMP Securities Adjusts Price Target on Aquestive Therapeutics to $10 From $8, Maintains Market Outperform Rating	MT
24-03-11	HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $7 From $6, Maintains Buy Rating	MT
24-03-07	Wedbush Lifts Aquestive Therapeutics' PT to $9 From $4 After Model Adjustments, Keeps Outperform Rating	MT
23-11-08	HC Wainwright Raises Price Target on Aquestive Therapeutics to $6 From $5, Maintains Buy Rating	MT
23-08-10	Wedbush Lifts Aquestive Therapeutics' Price Target to $4 From $3 Due to Decreased Share Count, Keeps Outperform Rating	MT
23-07-03	Wedbush Trims Aquestive Therapeutics' PT to $3 From $4, Pushes US, EU Launch Estimates for Anaphylm/Anaphylaxis; Keeps Outperform Rating	MT
23-03-09	Wedbush Upgrades Aquestive Therapeutics to Outperform Rating From Neutral, Adjusts Price Target to $4 From $3	MT
23-01-31	Wedbush Downgrades Aquestive Therapeutics to Neutral From Outperform, Notes Limited Cash Runway; Trims Price Target to $3 From $4	MT
22-11-04	Alliance Global Partners Adjusts Price Target on Aquestive Therapeutics to $7 From $10, Maintains Buy Rating	MT
22-09-07	Oppenheimer Initiates Coverage on Aquestive Therapeutics With Outperform Rating, $8.50 Price Target	MT
22-09-06	HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $5 From $6, Reiterates Buy Rating	MT
22-09-01	BMO Capital Adjusts Aquestive Therapeutics' Price Target to $6 from $9, Maintains Outperform Rating	MT
22-08-30	Alliance Global Initiates Aquestive Therapeutics at Buy Rating With $10 Price Target	MT
22-08-04	Wedbush Adjusts Price Target on Aquestive Therapeutics to $4 From $8 on Potential Share Count Increase; Outperform Rating Kept	MT
22-06-21	HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $5 From $8, Reiterates Buy Rating	MT
22-05-31	HC Wainwright Adjusts Aquestive Therapeutics' Price Target to $8 From $14, Keeps Buy Rating	MT
22-03-10	Wedbush Adjusts Aquestive Therapeutics' Price Target to $8 From $26, Removes Libervant From Pipeline Valuation; Outperform Rating Kept	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AQUESTIVE THERAPEUTICS, INC.					+81.23%
	ELI LILLY AND COMPANY					+17.02%
	JOHNSON & JOHNSON					+3.71%
	ABBVIE INC.					+10.32%
	ROCHE HOLDING AG					+7.48%
	NOVARTIS AG					+11.26%
	ASTRAZENECA PLC					+34.37%
	AMGEN INC.					-0.65%
	NOVO NORDISK A/S					+7.36%
	GILEAD SCIENCES, INC.					+8.07%
	Average					+18.02%
	Weighted average by Cap.					+11.55%